Catabasis Pharmaceuticals Inc., of Cambridge, Mass., said a three-part series of Phase I studies showed that CAT-1004, a SMART Linker conjugate of docosahexaenoic acid (DHA) and salicylate created using the company's technology, was safe and well tolerated. Data also showed that the conjugated compound was absorbed following oral administration and metabolized to its active components intracellularly, providing proof of concept for the SMART Linker platform.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST